



# DRAFT INTERNATIONAL STANDARD ISO/DIS 17351

ISO/TC 122

Secretariat: JISC

Voting begins on  
2011-11-29

Voting terminates on  
2012-04-29

INTERNATIONAL ORGANIZATION FOR STANDARDIZATION • МЕЖДУНАРОДНАЯ ОРГАНИЗАЦИЯ ПО СТАНДАРТИЗАЦИИ • ORGANISATION INTERNATIONALE DE NORMALISATION

## Packaging — Braille on packaging for medicinal products

*Emballage — Braille sur les emballages destinés aux produits médicaux*

ICS 55.020

In accordance with the provisions of Council Resolution 15/1993 this document is circulated in the English language only.

Conformément aux dispositions de la Résolution du Conseil 15/1993, ce document est distribué en version anglaise seulement.

To expedite distribution, this document is circulated as received from the committee secretariat. ISO Central Secretariat work of editing and text composition will be undertaken at publication stage.

Pour accélérer la distribution, le présent document est distribué tel qu'il est parvenu du secrétariat du comité. Le travail de rédaction et de composition de texte sera effectué au Secrétariat central de l'ISO au stade de publication.

THIS DOCUMENT IS A DRAFT CIRCULATED FOR COMMENT AND APPROVAL. IT IS THEREFORE SUBJECT TO CHANGE AND MAY NOT BE REFERRED TO AS AN INTERNATIONAL STANDARD UNTIL PUBLISHED AS SUCH.

IN ADDITION TO THEIR EVALUATION AS BEING ACCEPTABLE FOR INDUSTRIAL, TECHNOLOGICAL, COMMERCIAL AND USER PURPOSES, DRAFT INTERNATIONAL STANDARDS MAY ON OCCASION HAVE TO BE CONSIDERED IN THE LIGHT OF THEIR POTENTIAL TO BECOME STANDARDS TO WHICH REFERENCE MAY BE MADE IN NATIONAL REGULATIONS.

RECIPIENTS OF THIS DRAFT ARE INVITED TO SUBMIT, WITH THEIR COMMENTS, NOTIFICATION OF ANY RELEVANT PATENT RIGHTS OF WHICH THEY ARE AWARE AND TO PROVIDE SUPPORTING DOCUMENTATION.

**iTeh STANDARD PREVIEW**  
(standards.iteh.ai)  
Full standard:  
<https://standards.iteh.ai/catalog/standards/sist/677ecd27-b1ae-47ed-9e93-a70e8e42d1ef/iso-17351-2013>

### Copyright notice

This ISO document is a Draft International Standard and is copyright-protected by ISO. Except as permitted under the applicable laws of the user's country, neither this ISO draft nor any extract from it may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, photocopying, recording or otherwise, without prior written permission being secured.

Requests for permission to reproduce should be addressed to either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
Case postale 56 • CH-1211 Geneva 20  
Tel. + 41 22 749 01 11  
Fax + 41 22 749 09 47  
E-mail [copyright@iso.org](mailto:copyright@iso.org)  
Web [www.iso.org](http://www.iso.org)

Reproduction may be subject to royalty payments or a licensing agreement.

Violators may be prosecuted.

# Contents

Page

Foreword .....	iv
Introduction.....	v
<b>1 Scope .....</b>	<b>1</b>
<b>2 Terms and definitions .....</b>	<b>1</b>
<b>3 General requirements for medicinal product packaging .....</b>	<b>2</b>
<b>3.1 Product identification.....</b>	<b>2</b>
<b>3.1.1 Information in Braille.....</b>	<b>2</b>
<b>3.1.2 Braille text placement .....</b>	<b>2</b>
<b>3.2 Braille spacing convention.....</b>	<b>2</b>
<b>3.3 Braille character sets .....</b>	<b>2</b>
<b>4 Determination of Braille legibility .....</b>	<b>2</b>
<b>4.1 Principles of Braille legibility compliance .....</b>	<b>2</b>
<b>4.2 Braille cell dot height .....</b>	<b>2</b>
<b>4.3 Altered Braille labelling.....</b>	<b>3</b>
<b>Annex A (normative) Methods of verification .....</b>	<b>4</b>
<b>A.1 Braille cell dot height measurement.....</b>	<b>4</b>
<b>A.2 Product identification by Braille legibility testing.....</b>	<b>4</b>
<b>Annex B (informative) Braille characteristics and recommendations.....</b>	<b>5</b>
<b>B.1 Braille character sets .....</b>	<b>5</b>
<b>B.2 The Braille cell .....</b>	<b>5</b>
<b>B.3 Marburg Medium spacing convention for Braille.....</b>	<b>6</b>
<b>Annex C (informative) Technology for the application of Braille to packaging for medicinal products .....</b>	<b>7</b>
<b>C.1 General .....</b>	<b>7</b>
<b>C.2 Embossing .....</b>	<b>7</b>
<b>C.3 Screen-printing .....</b>	<b>9</b>
<b>C.4 Other production methods .....</b>	<b>9</b>
<b>C.4.1 General .....</b>	<b>9</b>
<b>C.4.2 Containers with integral Braille .....</b>	<b>9</b>
<b>C.4.3 Containers with adhesive labels.....</b>	<b>9</b>
<b>C.5 Packaging supplier controls .....</b>	<b>9</b>
<b>C.5.1 Identification of Braille tooling.....</b>	<b>9</b>
<b>C.5.2 In-process controls .....</b>	<b>9</b>
<b>C.6 MAH incoming control checks .....</b>	<b>9</b>
<b>Annex D (informative) Guidance on Braille specifications and artwork generation.....</b>	<b>11</b>
<b>Annex E (informative) Braille character sets.....</b>	<b>13</b>
<b>Bibliography.....</b>	<b>14</b>

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 17351 was prepared by Technical Committee ISO/TC 122, *Packaging*.

**iTeh STANDARD PREVIEW**  
(standards.iteh.ai)  
Full standard:  
<https://standards.iteh.ai/catalog/standards/sist/677ecd27-b1ae-47ed-9e93-a70c8e42d1ef/iso-17351-2013>

## Introduction

This standard has been developed to meet various national and regional requirements for Braille on packaging for medicinal products, and technical constraints and user requirements, to harmonise technical standardisation and specifications. It is considered that the knowledge and experience that has been gained in EN 15823 may be used for the development of this ISO Standard.

The background for the creation of a European Standard for Braille on packaging for medicinal products (EN 15823) was a European Directive issued in 2004 by the European Commission (Council Directive 2004/27/EC). This Directive requires Braille labelling on outer packaging for medicinal products within the European Union. In practice it means that basically the name of the medicinal product and where appropriate the form and strength has to be in Braille as an aid to identification for blind and partially sighted people.

Braille will continue to be an essential means of communication for Blind and visually impaired people around the world. Once other accessible packaging technologies emerge additional standards may be created to complement this standard.

**iTeh STANDARD PREVIEW**  
(standards.iteh.ai)  
Full standard:  
<https://standards.iteh.ai/catalog/standards/sist/677ecd27-b1ae-47ed-9e93-a70e8e42d1ef/iso-17351-2013>

**iTeh STANDARD PREVIEW**  
**(standards.iteh.ai)**

Full standard:  
<https://standards.iteh.ai/catalog/standards/sist/677ecd27-b1ae-47ed-9e93-a70e8e42d1ef/iso-17351-2013>

# Packaging — Braille on packaging for medicinal products

## 1 Scope

This document specifies requirements and provides guidance for the application of Braille to the labelling of medicinal products.

NOTE 1 The labelling of medicinal products placed on the market and incorporating Braille in accordance with this document meets the requirements of European Directive 2001/83/EC, Article 56, (a) as amended by Directive 2004/27/EC [1].

NOTE 2 The principles in this document can be applied in other sectors, as appropriate.

## 2 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

### 2.1

#### **Braille**

tactile reading and writing system composed of Braille cells

### 2.2

#### **Braille cell**

series of up to six raised dots set out in a domino-type cell

### 2.3

#### **burst-through**

cracking, breaking, pin-holing of the coating or material surface, visible to the naked eye, caused by the process of embossing Braille

### 2.4

#### **labelling**

information on the immediate or outer packaging

### 2.5

#### **Marburg Medium spacing convention**

defined system of dimensions within and between the Braille cells

NOTE The Marburg Medium spacing convention for Braille [4] is recommended in the European Commission Guidance [3] for use for medicinal product labelling.

### 2.6

#### **marketing authorization holder**

#### **MAH**

natural or legal person or entity responsible for placing the medicinal product on the market

### 3 General requirements for medicinal product packaging

#### 3.1 Product identification

##### 3.1.1 Information in Braille

The approved Braille text on the labelling shall include the information as required in the country in which the product is to be supplied.

NOTE 1 Guidance on the information to be labelled in Braille is given in the European Commission Guidance [3].

NOTE 2 It might be necessary to include Braille text on more than one panel in order to accommodate the legally required information ensuring that Braille cell dots do not compromise any printed text.

##### 3.1.2 Braille text placement

The placement of Braille text shall not reduce the legibility of printed text for sighted people.

NOTE 1 This is indicated when, for example, the application of Braille corrupts printed text and graphics.

NOTE 2 The MAH is encouraged to place the Braille away from printed text and graphics, where possible.

#### 3.2 Braille spacing convention

The MAH shall specify the Braille spacing convention to be used. The use of Marburg Medium spacing convention is highly recommended unless there is a specific national requirement.

#### 3.3 Braille character sets

The MAH shall identify and specify the Braille character set appropriate to the market in which the product is to be supplied, see Annex E.

### 4 Determination of Braille legibility

#### 4.1 Principles of Braille legibility compliance

The Braille text shall enable Braille readers to identify the medicinal product.

Compliance with the Braille cell dot height limits (see 4.2) is evidence of compliance with the text legibility requirement.

If the MAH does not specify compliance with the Braille cell dot height requirements (see 4.2 and A.1) then legibility testing shall be carried out in accordance with A.2.

#### 4.2 Braille cell dot height

In order to ensure that Braille readers can identify the name of the medicinal product, the Braille cell dot height of production samples when measured in accordance with A.1 at the packaging (e.g. carton or label) manufacturer's site shall be:

- a) for embossed materials the target Braille cell dot height shall be 0,20 mm with not more than 5 % of Braille cell dot height measurements lower than 0,12 mm and not more than 1 % of Braille cell dot height measurements lower than 0,10 mm;
- b) for other Braille production methods, e.g. screen-printed labels, the target Braille cell dot height shall be 0,20 mm, with not more than 5 % of Braille cell dot height measurements lower than 0,16 mm.

NOTE 1 The MAH and packaging manufacturer are encouraged to aim for a higher cell dot height in line with the packaging manufacturer's processes. Cardboard is not an engineering material and considerations relating to Braille cell



dot formation contained within Annex C should be taken into account in order to achieve Braille cell dot height requirements.

NOTE 2 Burst-through can occur when the substrate or any surface coating fractures causing damage to print and/or surface finish. Burst-through is not recommended, but might be accepted by certain markets, however the presence of burst-through should not in itself constitute a valid reason for batch rejection.

NOTE 3 Braille dots should not compromise any printed text whether the dots are intact or are formed with a burst-through.

NOTE 4 The Braille cell dot height limits included above reflect technical issues associated with the production of pharmaceutical packaging – they do not necessarily represent a Braille cell dot height that can be achieved with other media.

### 4.3 Altered Braille labelling

Braille shall not be obscured by labels or any other adhesive devices, with only one exception: where Braille needs to be altered, the new Braille text should cause the original Braille text to be totally obscured.

**iTeh STANDARD PREVIEW**  
(standards.iteh.ai)  
Full standard:  
<https://standards.iteh.ai/catalog/standards/sist/677ecd27-b1ae-47ed-9e93-a70c8e42d1ef/iso-17351-2013>

## Annex A (normative)

### Methods of verification

#### A.1 Braille cell dot height measurement

The number of samples and the method of measurement shall be agreed between the customer and supplier. The Braille cell dot height shall be measured along the Braille text in at least three places.

The Braille cell dot height can be measured using a calibrated, spring-loaded (spring-force not less than 0,5 N) micrometer with an anvil that covers at least three Braille dots in a cell, see [5]. Measurement of the Braille cell dot height shall use cells containing at least three dots. Alternative methods may be used provided that they are of at least equivalent precision and accuracy.

Measurements can be performed with two decimal places and results shall be reported to two decimal places.

NOTE It is recommended that random checks are carried out across all stations, see C.5.2. Checks should also be made to ensure the readability of underlying printed text.

#### A.2 Product identification by Braille legibility testing

It is not necessary to undertake legibility testing for each batch provided that the Braille specification applied has been adequately validated.

If the Braille cell dot height requirement (see 4.2) cannot be verified then samples can be tested for Braille legibility by organisations representing blind and partially sighted people or other suitable organisations.

NOTE Testing should be carried out on an agreed protocol taking into account the following factors:

- a) The qualification and number of the blind Braille readers used in the test;
- b) Separate testing of embossed cartons and labels if it is necessary to test the two types of packaging;
- c) Establishing the minimum Braille cell dot height that results in product identification.